Journal of Psychiatry Reform
  • About us
  • How to Contribute
  • FAQ
  • Contact us
ISSN 2371-4301
Search
  • Home
  • Editorials & Commentary
  • Papers
    • Review Articles
  • Abstracts
  • Educational Programs
  • Members
  • Contact us
Agomelatine: is it really a firstline drug?
  • March 25, 2018,
  • 0Comments

  Vol 3 #2 March 2018   Agomelatine is listed as a firstline medication for the treament of depression in a number of guidelines including Canadian Guidelines. This is the case eventhough Agomelatine is not approved for use in Canada..

  • Posted by Editor JPR
  • Posted in Abstracts,Brief Review
Should Canadian patients look forward to aducanumab for Alzheimer disease?
  • September 12, 2021,
  • 0Comments

Journal of Psychiatry Reform Vol 10 #12 This is an Open Access article from CMAJ distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence. Open Access Should Canadian patients look forward to aduca..

  • Posted by Alan Eppel
  • Posted in Creative Commons Republished,Editorials & Commentary
Creative Commons License
This work is licensed under a Creative Commons Attribution Non-Commercial No-Derivatives 4.0 International License.